Acute lymphoblastic leukemia (ALL) in infants under 1 year is strongly associated with translocations involving 11q23 (MLL gene), CD10-negative B-lineage (proB) immunophenotype, and poor outcome. The present study analyses the relationship between age, MLL rearrangements, proB-lineage, and in vitro drug resistance determined using the MTT assay. Compared to 425 children aged over 1 year with common/preB (c/preB) ALL, the 44 infants were highly resistant to steroids (for prednisolone (PRED) more than 580-fold, P ¼ 0.001) and L-asparaginase (L-ASP) (12-fold, P ¼ 0.001), but more sensitive to cytarabine (AraC) (1.9-fold, P ¼ 0.001) and 2-chlorodeoxyadenosine (2-CdA) (1.7-fold, Po0.001). No differences were found for vincristine, anthracyclines, thiopurines, epipodophyllotoxines, or 4-hydroperoxy (HOO)-ifosfamide. ProB ALL of all ages had a profile similar to infant ALL when compared with the group of c/ preB ALL: relatively more resistant to L-ASP and PRED (and in addition thiopurines), and more sensitive to AraC and 2-CdA. Age was not related to cellular drug resistance within the proB ALL group (o1 year, n ¼ 32, vs X1 year, n ¼ 19), nor within the MLL-rearranged ALL (o1 year, n ¼ 34, vs X1 year, n ¼ 8). The translocation t(4;11)(q21;q23)-positive ALL cases were more resistant to PRED (47.4-fold, P ¼ 0.033) and 4-HOO-ifosfamide (4.4-fold, P ¼ 0.006) than those with other 11q23 abnormalities. The expression of P-glycoprotein, multidrug-resistance protein, and lung-resistance protein (LRP) was not higher in infants compared to older c/preB ALL patients, but LRP was higher in proB ALL and MLL-rearranged ALL of all ages. In conclusion, infants with ALL appear to have a distinct in vitro resistance profile with the proB immunophenotype being of importance. The role of MLL cannot be excluded, with the t(4;11) being of special significance, while age appears to play a smaller role.
Introduction
While children with acute lymphoblastic leukemia (ALL) nowadays have greatly improved outcome, infants under 1 year of age with ALL still have a poor prognosis.
1,2 ALL in infants often presents with a number of unfavorable clinical features such as hyperleukocytosis, organomegaly, and CNS involvement. Favorable cell biological characteristics (hyperdiploidy, TEL-AML1 fusion) are seldom found in infant ALL, whereas myeloid-associated antigen coexpression is common. Importantly, infant ALL is closely associated with MLL gene rearrangements and proB (pre-preB/immature/CD10-negative precursor-B) immunophenotype. 1 MLL gene rearrangements arise from fusions of this gene at 11q23 with a great number of partner genes. In ALL, the most common partner is the AF4 gene on chromosome 4q21 (reviewed by Rubnitz et al), 3 resulting in a t(4;11)(q21;q23).
It is not clear which of the features associated with infant ALL specifically contribute to the poor treatment outcome. Infants with MLL rearrangements in general, but possibly more specifically MLL-AF4 fusion, appear to have a poor prognosis. 4, 5 Early in vivo response to PRED was found to be predictive of outcome in infant ALL in the German Berlin-Frankfurt-Mü nster (BFM) studies. 6 We have already shown that infants with ALL, and patients with proB ALL are more in vitro resistant to glucocorticoids and L-asparaginase (L-ASP). Moreover, both infants o1 year and proB ALL cases were relatively in vitro sensitive to cytarabine (AraC). 7 However, it is unclear which of the factors (age, MLL rearrangements, or immunophenotype) is responsible for this specific profile.
The drug-efflux pump proteins, permeability-glycoprotein (Pgp/MDR1) and MDR-associated protein (MRP1), as well as the lung-resistance protein/major vault protein (LRP/MVP), are associated with resistance to anthracyclines, vinca-alkaloids, and epipodophyllotoxins. LRP was first described in an anthracycline-resistant non-small-cell lung cancer lacking P-gp expression. [8] [9] [10] [11] [12] It is not known whether PGP, MRP, or LRP have any role in the drug-resistance pattern of infant ALL.
In this study, we have measured the in vitro resistance profile of a large series of infant ALL and compared it with the profile of noninfant childhood ALL cases to determine the contribution of age, immunophenotype, and MLL status to the infant ALL response to drug therapy. Furthermore, we have determined the expression of MDR proteins in infants in relation to cellular drug resistance.
Materials and methods

Patients and leukemic cell samples
In total, 44 children under 1 year of age with newly diagnosed, untreated ALL from the Dutch Childhood Leukemia Study Group (DCLSG), the German Co-operative ALL (COALL) study group, the BFM Study Group, and the Pediatric Oncology Group (POG) were studied. Nine of these cases (from DCLSG and COALL study groups) have been published previously. 7 The infants in the present study were compared to a reference group of 425 cases of childhood c/preB ALL older than 1 year previously tested in our laboratory, as well as to 19 proB ALL X1 year from the DCLSG, COALL, and BFM study groups. All samples were obtained after appropriate informed consent within approved protocols from the participating institutions.
Immunophenotyping and DNA index flow cytometry were performed at reference laboratories of the participating groups following standard procedures. Patient characteristics (gender, age, white blood cell count (WBC) at diagnosis) were collected by study centers. Precursor B-cell immunophenotype was defined as HLA-DR þ /terminal deoxynucleotidyl transferase (TdT) þ /CD19 þ . This was further differentiated as follows: proB
þ ) sample older than 1 year was included with a translocation involving the MLL gene (t(11;19)( q23;p13)).
Leukemic cells from bone marrow or peripheral blood of ALL patients were isolated within 48 h of sampling by density gradient centrifugation (Lymphoprep, 1.077 g/ml, Nycomed Pharma, Oslo, Norway; at 480 g for 15 min). After washing, the cells were resuspended in RPMI 1640 (Dutch modification; Gibco BRL, Breda, The Netherlands) containing 20% fetal calf serum (Gibco BRL) and other supplements. 13 When necessary, contaminating normal cells were removed by monoclonal antibodies linked to magnetic beads as described previously. 14 All samples used to test drug resistance contained more than 80% leukemic cells at the time of culturing, as determined by cytospin preparations stained with May-Grü nwald-Giemsa (Merck, Darmstadt, Germany). It has been previously shown that neither the source of the leukemic cells (bone marrow or peripheral blood) 15 nor cryopreservation 16 affects the drug resistance measured.
Detection of MLL gene rearrangements
Detection of translocations involving the MLL gene at chromosome 11q23 was based on cytogenetic analysis and/or molecular (genetic) techniques: Southern blotting, 17 reverse transcriptase-polymerase chain reaction (RT-PCR), or fluorescence in situ hybridization (FISH). Germline MLL gene status of infants and proB ALL cases was based on Southern blotting or FISH.
Southern blot analysis for MLL rearrangements was performed as described elsewhere. 17 RNA isolation and reverse transcription for the RT-PCR were performed. 18 Amplification of the following MLL fusions genes was performed as published previously:
19 MLL-AF4 (t(4;11)(q21;q23)), MLL-AF9 (t(9;11)(p22;q23)), and MLL-LTG, -ENL or -ELL (t(11;19) (q23;p21))].
Dual-colored FISH experiments for the detection of translocations of the MLL gene were performed with an MLL upstream probe (MLL-U) covering exons 1-7 of the MLL gene and a downstream probe (MLL-D) covering the exons 28-37 of the MLL gene. 20 Nick translation was used to label the probes with digoxygenin-11-dUTP (cosmid for MLL-U) and biotin-16-dUTP (cosmid for MLL-D). 21 The interphase FISH analysis was performed on cytospins stored at À201C according to standard procedures. 22 A minimum of 200 nuclei each were scored blind by two independent observers. In MLL germline patients, two fusion spots are seen in the interphase nuclei, while positive patients show one fusion spot and one green and one red spot. 20 In vitro drug-resistance assay In vitro drug cytotoxicity was determined in the MTT assay as described previously. 13,15. This assay is based on the principle that yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide (MTT), which is added to the leukemic cells after culture, is reduced to purple-blue formazan crystals by the living cells only, which can be detected by spectrophotometry. The cells incubated without drugs (ie control wells) are set at 100% survival and used to calculate that concentration of each cytostatic drug lethal to 50% of the cells (LC 50 ). The ranges of drug concentrations used were based on earlier studies and aimed at obtaining an LC 50 value both for highly sensitive and resistant cases. The following drugs and range of concentrations (six for each drug) were used: PRED disodium phosphate, 0.08-250 mg/ml; dexamethasone sodium phosphate, 0.0002-6.0 mg/ ml; vincristine, 0.05-50 mg/ml; L-ASP, 0.003-10 IU/ml; daunorubicin, 0.002-2.0 mg/ml; doxorubicin, 0.008-8.0 mg/ml; idarubicin, 2.0-0.002 mg/ml; mitoxantrone, 0.001-1.0 mg/ml; 6-mercaptopurine (6-MP), 15.6-500 mg/ml; 6-thioguanine (6-TG), 1.6-50 mg/ml; AraC, 0.04-2.5 mg/ml; 2-CdA, 0.0004-40 mg/ml (kindly provided by Ortho Biotech, Raritan, NJ, USA); etoposide, 0.05-50 mg/ml; teniposide, 0.003-8.0 mg/ml; and 4-HOO-ifosfamide, 0.10-100 mg/ml (kindly provided by Asta Medica, Frankfurt am Main, Germany).
Multidrug-resistance proteins P-gp was detected with the monoclonal antibody MRK16 (Kamiya Biomedical Company, Thousand Oaks CA, USA), MRP1 and LRP expression was detected by MRPr1 and LRP56, respectively (kind gifts of Prof Dr RJ Scheper, Department of Pathology, VU University Medical Center). The flow cytometry for the expression of the drug-resistance proteins was performed as described previously. 23 Nonspecific isotype-matched antibodies using the same fixative and IgG concentration as the specific antibodies, as well as omission of the primary antibody, were used as controls for aspecific staining. The fluorescence index (FI) was used as a measure of protein expression by flow cytometry: the ratio between the mean fluorescence intensity of the leukemic cells stained with the specific antibody and that of the aspecific isotype-matched antibody. The leukemic cells were gated by forward and sideward scatter properties.
Statistics
LC 50 values for the drugs tested were compared using the MannWhitney U (MWU) test. Since the LC 50 values were not normally distributed, also not after log-transformation of the LC 50 values, multiple logistic regression (forward entry) was used in the analysis of the role of commonly coexpressed features in drug resistance. The median LC 50 value of each drug for the entire patient group was used to divide the patients into relatively sensitive and relatively resistant patients. Table 1 shows the clinical and biological characteristics of the 44 infants with ALL, compared with those of 51 cases of proB ALL and 42 cases of MLL-rearranged ALL available for this study.
Results
Drug-resistance profile in infant ALL
The drug-resistance profiles of 44 infants with ALL were compared with those of 425 samples of c/preB ALL childhood patients above 1 year of age (Table 2) . Infant ALL cells were highly resistant to glucocorticoids (for PRED more than 580-fold higher median LC 50 , P ¼ 0.001; for dexamethasone (DEX) median 55-fold difference, P ¼ 0.040) and L-ASP (12-fold, P ¼ 0.001) compared to the other group ( Figure 1 : graphic representation for six of the drugs, results for all 12 drugs summarized in Table 2 ). However, the infant ALL cells were not more resistant to any of the other drugs tested, notably not to vincristine, daunorubicin and other anthracyclines, thiopurines, 4-HOO-ifosfamide, or epipodophyllotoxins (see Table 2 ). The infant ALL cells were significantly more sensitive to AraC (1.9-fold, P ¼ 0.001) and 2-CdA (1.7-fold, Po0.001) compared to the c/preB ALL samples of children X1 year ( Figure 1 ). Comparing infants with ALL with all B-lineage ALL cases above 1 year (ie including 19 proB 4 1 year in the latter group) made no difference to the above results.
Some cases of infant ALL cells displayed a drug-induced increase in cell survival and growth after 4 days of culture. In 6/ 44 (14%) of the infant cases, the optical density, that is cell concentration, was higher for cells incubated with glucocorticoids than in the control wells not exposed to drugs (PRED n ¼ 5, DEX n ¼ 1). These six infant ALL cases had the proB immunophenotype. Three out of 19 (16%) proB cases X1 year also displayed this phenomenon with PRED. However, only 3% of the c/preB cases X1 year responded similarly to glucocorticoids.
To further investigate which factor (age, phenotype, or MLL rearrangement) is primarily responsible for the drug-resistance profile described above for infant ALL, we studied each in turn, correcting for the other variables as much as possible.
Age and drug resistance
Resistance data were obtained from 32 proB samples o1 year and 19 cases with proB immunophenotype older than 1 year. Within these 51 samples, the drug-resistant profile for the infants did not differ from that of the older children with proB, especially not for glucocorticoids, L-ASP, AraC, or 2-CdA. Within the MLL-rearranged cases, no significant differences in cellular drug resistance were observed on comparing 34 ALL o1 year with eight cases X1 year.
Within c/preB ALL, only 10 samples o1 year were available for comparison with the 425 c/preB cases older than 1 year. The infant c/preB ALL were significantly more sensitive to AraC (median 2.5-fold difference, P ¼ 0.009; o1 year: n ¼ 5, median ¼ 0.26 mg/ml, range 0.09-0.34; 41 year: n ¼ 281, median ¼ 0.49 mg/ml, range 0.04/ÀS2.5) and vincristine (median 6.6-fold, P ¼ 0.004; o1 year: n ¼ 8, median ¼ 0.11 mg/ml, range 0.04-10.8; 41 year: n ¼ 350, median ¼ 0.69 mg/ml, range 0.05/ÀS50). However, the infant c/preB ALL group was not more resistant to the other six classes of drugs tested, notably not to glucocorticoids or L-ASP.
Infants aged 0-5 months (n ¼ 26) did not differ in in vitro drug resistance from those 6-11 months old (n ¼ 18). This was also the case when 0-3 month-old infants were compared with the rest of the infants, or when the infants were divided into 0-3-, 4-6-, 7-9-, and 10-12-month-old groups and analyzed for a trend using the Kruskal-Wallis test. The same results were obtained when the comparisons were performed within only CD10
-cases or only MLL-rearranged cases.
In conclusion, age does not determine the drug-resistance profile when infants are compared to older children within the homogenous subgroups of, respectively, proB ALL or Table 1 Clinical and biological characteristics of ALL patients defined by infant age, proB immunophenotype or MLL gene rearrangements Drug-resistance profile in infant ALL NL Ramakers-van Woerden et al MLL gene rearranged ALL. However, age may play some role in c/preB ALL, especially with regard to AraC (one of the drugs the infant ALL as a whole are comparatively sensitive to compared to older c/preB ALL samples) and vincristine drug sensitivity.
Immunophenotype and drug resistance
The 51 proB ALL cases (n ¼ 32 o 1 year and n ¼ 19 X1 year) were resistant to steroids (PRED median 4581-fold, P ¼ 0o0.001; DEX: 8.1-fold, P ¼ 0.012), L-ASP (13.1-fold, Po0.001), and also to 6-MP (2.2-fold, P ¼ 0.002) and 6-TG (1.6-fold, P ¼ 0.002), compared to 435 c/preB ALL n ¼ 10 o1 year and n ¼ 425 X1 year) (see Table 3 ). Also, the proB cases were relatively sensitive to AraC (median 1.5-fold, P ¼ 0.003) and to 2-CdA (1.9-fold, Po0.001). These results were similar when only samples of patients X1 year were compared. Infants (o1 year) with proB ALL (n ¼ 32) did not differ in cellular drug resistance from infants with c/preB ALL (n ¼ 10, Figure 2 ) for all eight classes of drugs tested, although the proB cases were much more resistant to PRED (more than 690-fold), with borderline significance (P ¼ 0.067).
There were too few cases of c/preB with a rearranged MLL gene to perform comparisons between proB and c/preB immunophenotypes with this genetic abnormality.
Hence, cellular resistance within the proB ALL immunophentype closely correlates with the drug-resistance profile characteristic of infants. It is not possible to rule out the effect of MLL rearrangements due to small numbers.
MLL gene rearrangements and drug resistance
The 42 MLL-rearranged samples (n ¼ 34 o1 year and n ¼ 8 X1 year) were more resistant to glucocorticoids (for PRED median 4568-fold, Po0.001; for DEX 80-fold, P ¼ 0.006) and L-ASP (11.4-fold, P ¼ 0.001), and more sensitive to AraC and 2-CdA (1.7-fold, P ¼ 0.004, and 1.9-fold, Po0.001, respectively), compared to 435 non-MLL gene rearranged cases. In addition, the MLL-rearranged cases were median 2.1-fold more sensitive to etoposide, compared to the non-MLL-rearranged patient samples (P ¼ 0.038). For the thiopurines, teniposide, and 4-HOO-ifosfamide, no significant differences were seen.
Within the infant group, only five cases with cellular resistance data had confirmed germline MLL gene status, as determined by Southern blotting (n ¼ 2) or FISH (n ¼ 3). These five cases did not show any striking differences in drugresistance profiles compared to the MLL-rearranged infants (all drug classes tested; the most clinically relevant drugs shown in Table 2 Relationship between age and in vitro drug resistance in precursor B-cell ALL 2-CdA ¼ 2-chlorodeoxyadenosine.
Figure 1
Relationship between age and in vitro drug resistance in childhood ALL. Infant (o1 year) ALL compared with c/preB ALL reference group X1 year. The boxes represent the 25 th -75 th percentile with the median shown as a horizontal bar, the whiskers give the minimum and maximum values. LC 50 values are expressed as mg/ml except for L-ASP: IU/ml. P-values were determined by the MannWhitney U test.
Drug-resistance profile in infant ALL
NL Ramakers-van Woerden et al Figure 3 : compare left two columns). However, with these small numbers, no final conclusions can be drawn. For the same reason, it was not possible to examine the impact of MLL gene rearrangements within immunophenotypic subgroups: proB-(only four germline MLL proB cases for comparison) or c/preBlineage ALL (only four rearranged MLL c/preB cases, all of which were infants).
MLL translocation partner genes: In 13/42 cases, the rearrangement of the MLL gene was only detected by Southern blotting, hence the partner genes were unknown. In the remaining 29 samples, 16 (55%) had a translocation with the AF4 gene at 4q21, seven had a translocation with 19p13, 5 with 9p22, and one had a translocation t(1;11)(p32;q23). The t(4;11)(q21;q23) samples were compared to those cases that were known to have an MLL gene rearrangement without involvement of the AF4 gene (n ¼ 18, including a number of 
Figure 2
Relationship between in vitro drug resistance and proBimmunophenotype in infant ALL. C/preB-lineage compared with proB ALL infants (o1 year). MLL germline case is represented by white, MLL rearranged by black, and uncertain MLL status by gray symbols. Individual LC 50 values for patient samples are shown; median values are represented by a horizontal bar. LC 50s are expressed as mg/ml except for L-ASP (IU/ml). P-values were determined by the MannWhitney U test. samples with unknown partner gene but negative PCR for MLL-AF4 fusion). When all ages were included, the t(4;11)(q21;q23) cells were significantly more resistant to PRED (413.6-fold, P ¼ 0.014) and 4-HOO-ifosfamide (three-fold, P ¼ 0.007, fewer samples tested) than cases with other 11q23 abnormalities (see Figure 4 , also illustrating the results for L-ASP and AraC, since these drugs were also important in the infant drug-resistance profile). Within the infant age group alone, cases with MLL-AF4 gene fusion remained relatively more resistant to PRED (47.4-fold, P ¼ 0.033) and 4-HOO-ifosfamide (4.4-fold, P ¼ 0.006), as well as resistant to 6-TG (2.0-fold, P ¼ 0.045), compared to cases with other translocations involving the MLL gene. No differences were seen for the other drugs tested.
Hence, it is possible that MLL gene rearrangements, especially MLL-AF4 gene fusion, contribute to cellular resistance in (infant) ALL.
Multiple regression analysis
In order to further analyze the contribution of the commonly coexpressed features, multiple logistic regression was applied for each of the drugs characteristic of the infant ALL cellular resistance profile in terms of the variables age (below or above 1 year), immunophenotype (proB or c/preB), and MLL status (rearranged or germline).
The following results, summarized in Table 4 , must be regarded with caution due to the small numbers of patients in certain subcategories. It is apparent that the influence of immunophenotype, age, and MLL status varies per drug. Thus, for PRED, a proB immunophenotype had more effect (associated with a 4.2-fold higher risk of a relatively resistant LC 50 value compared to the c/preB, P ¼ 0.0005) than age or MLL rearrangement. In contrast, age o1 year, but not immunophenotype or MLL rearrangement, was important for L-ASP resistance (odds ratio (OR) of 7.3, P ¼ 0.0015) and AraC sensitivity (OR ¼ 0.33, P ¼ 0.01). 2-CdA sensitivity (OR ¼ 0.10, P ¼ 0.0001) appeared to be associated with rearrangements involving the MLL gene.
Multidrug-resistance proteins
The expression of the multidrug-resistance proteins P-gp, MRP, and LRP could be determined for 19 infant ALL samples. No significant differences were found compared with the corresponding protein expression levels in 84 c/preB ALL cases older than 1 year.
The proB ALL samples (n ¼ 19, 12 of which o 1 year of age) had a median 1.4-fold higher expression of LRP compared with the c/preB ALL cases (median fluorescence index (p25-p75): 2.86 (2.02-3.50) and 2.06 (1.72-2.51), n ¼ 19 and 91, respectively; P ¼ 0.008). Increasing LRP expression within the proB samples was not significantly correlated with resistance to any drugs; for daunorubicin, a trend was observed with a Spearman correlation coefficient of 0.714, P ¼ 0.071 (n ¼ 7).
MLL-rearranged samples (n ¼ 15) had a median 1.3-fold higher expression of P-gp compared with non-MLL-rearranged cases (n ¼ 89; P ¼ 0.051) (median fluorescence index (p25-p75): 2.86 (2.02-3.50) and 2.06 (1.72-2.51), respectively).
Discussion
In this series of 44 ALL patients aged under 1 year, we find that the infant ALL cells have a distinct profile of in vitro resistance to Figure 4 Impact of t(4;11)(q21;q23) resulting in MLL-AF4 gene fusion on in vitro drug resistance in childhood ALL. In vitro resistance of MLL-AF4-positive cases compared with other MLL translocations within childhood ALL. Cases X1 year of age are indicated by a box. Individual LC 50 values for patient samples are shown; median values are represented by a horizontal bar. LC 50s are expressed as mg/ml except for L-ASP (IU/ml). P-values were determined by the MannWhitney U test. 24 However, using the in situ thymidylate synthase inhibition assay, we have no evidence for high resistance to methotrexate in infant ALL. 25 These results confirm our earlier findings in a small number of infants o1 year of age. 7 Importantly, we also confirmed in this larger series that infant ALL cells are highly sensitive to AraC, and, in addition, showed that the same was true for 2-CdA.
Infant cases form a distinct subgroup of ALL with a poor prognosis and display a pattern of features not commonly observed in ALL above 1 year of age. The CD10-negative proB immunophenotype and translocations involving the MLL gene (11q23) are special characteristics of this age group, the prevalence of which are inversely related to age.
In our study, age itself (or some coexpressing factor) was not directly responsible for the infant cellular resistance/sensitivity profile since (1) within proB ALL, cases o1 year of age do not differ from cases X1 year, especially not for glucocorticoids, L-ASP, AraC, or 2-CdA; and (2) within MLL-rearranged cases, also patients o1 year do not have a significantly different in vitro resistance profile compared to patients X1 year. However, the c/preB infants were more sensitive to AraC compared to the older c/preB; moreover, with multivariate logistic regression analysis, age appeared to be the most relevant factor associated with AraC sensitivity and L-ASP resistance.
When proB ALL was compared with c/preB ALL, all ages included, they had an in vitro resistance profile very similar to that of the infants with ALL (see also reference Pieters et al 7 ) , with resistance to glucocorticoids and L-ASP and sensitivity to AraC. This glucocorticoid and L-ASP resistance might contribute to the poorer prognosis of proB ALL compared to c/preB ALL.
The prognosis of infants lacking high-risk features (ie presenting with c/preB ALL, germline MLL lower white blood cell counts) has been reported to be not as favorable as that of their older counterparts. 26 The small to absent difference in drug resistance found in our study between proB and c/preB infants appears to correlate with this. However, there was a strong trend for resistance to PRED in proB compared to c/preB infants. Moreover, the presence of proB immunophenotype resulted in a significantly higher relative risk for being PRED resistant, as analyzed by multiple logistic regression. That this relationship was not found for DEX , although both drugs are thought to act on the same receptor, could be due to the relatively low number of infants tested for response to DEX. Based on the above findings, proB immunophenotype appears to be linked with glucocorticoid resistance. The underlying cause of glucocorticoid resistance in proB is yet unknown, but is subject of ongoing studies.
The high percentage of MLL rearrangements in infants with ALL in our series is in agreement with studies that also implement molecular techniques. [27] [28] [29] It is difficult to establish the relationship between MLL gene rearrangement and drug resistance. The majority of our MLL cases are aged o1 year, it is hence not surprising that the MLL-rearranged patients in our study have a similar cellular resistance profile to the one we found for infants with ALL.
The presence of translocations involving the MLL gene appeared to confer a significantly higher chance for relative sensitivity to 2-CdA, with the exclusion of the variables age and immunophenotype, as analyzed by multiple logistic regression.
The cellular resistance profile of MLL germline infants does not appear to differ substantially from MLL-rearranged cases. However, the numbers are very small, hence overinterpretation must be avoided, but the few MLL germline infants were, for instance, not remarkably sensitive to PRED or L-ASP. In a recent BFM Study Group report, MLL gene rearrangements lost their negative prognostic value in a multivariate analysis that included in vivo PRED response. 6 Our current data show that MLL-AF4-positive cases are more resistant to PRED, 4-HOO-ifosfamide, and (among infants only) 6-TG, which might explain why MLL-AF4-positive cases could have a poorer outcome than other MLL-rearranged infant ALL. 5, 30 Infant and 11q23 rearranged blast cells have previously been reported to have a higher than median cell recovery after culture on stromal layers. 31 Translocation t(4;11) ALL cells have been described to be relatively resistant to cell death following serum deprivation in vitro. 32 We have previously reported that blast cell survival and proliferation is stimulated by cytostatic drugs in a total of 4% of ALL cases, 2.5% due to glucocorticoids. 33 In the present study, a much higher percentage (14-16%) of infant and proB ALL cases showed this effect, especially due to glucocorticoids. One quarter of AML patient samples also displayed this phenomenon, which correlated with a poorer prognosis. 34 Hence, it appears that both proB/infant ALL and AML cells have a greater propensity for cellular stimulation by glucocorticoids in vitro, the exact contrary of the effect intended in vivo. The median (25 th -75 th percentile) control cell survival did not differ between the groups studied (c/preB ALL, infant, proB, and MLL-rearranged ALL: 68% (46-90%), 58% (46-76%), 60% (47-78%), and 54% (42-72%), respectively).
The in vitro resistance to glucocorticoids is in line with the observation by the BFM group that a relatively high proportion of infants are in vivo poor PRED responders. 6 In vitro resistance, especially to PRED, vincristine, and L-ASP, is a strong independent prognostic factor in childhood ALL. [35] [36] [37] [38] Early relapse is the major cause of the poor outcome in infant ALL, since more than 90% of the infants enter complete remission. Presumably, resistance to glucocorticoids and L-ASP, two major induction drugs in ALL protocols, contributes to this treatment failure.
The relative sensitivity of infant ALL cells to AraC and 2-CdA supports the use of AraC to more effectively treat infant ALL. The median LC 50 for 2-CdA in infant ALL is at least as low as in the AML patient group. 39 Infants have done better on protocols implementing high-dose AraC (among other drugs) during the consolidation phase, such as reported by the Dana-Farber Cancer Institute 40 and the CCG. 5 In addition, German adult proB ALL cases have showed an improved outcome, compared to preceding trials, following intensification of postremission therapy with high-dose AraC and mitoxantrone, both for cases with and without the t(4;11) translocation. 41 Infant ALL appeared not to have higher expression levels of Pgp, MRP, or LRP than ALL X1 year. This is in agreement with the data that infants are not more resistant to vincristine, anthracyclines, and epipodophyllotoxines. However, proB ALL of all ages had significantly higher LRP levels compared to c/ preB ALL. In a previous study of childhood ALL, LRP expression was weakly but significantly correlated to daunorubicin resistance. 12 Within proB ALL, there was no significant relationship between LRP expression and in vitro resistance to anthracyclines in the small number analyzed. There was a tendency for a correlation between LRP and daunorubicin but this was not significant (P ¼ 0.07). Future studies are needed to further explore the significance of LRP expression in proB ALL.
In conclusion, infants with ALL have a distinctive in vitro resistance profile. Resistance to glucocorticoids and L-ASP might contribute to their poor prognosis. The remarkably high sensitivity to AraC and 2-CdA suggests that infants with ALL might benefit from treatment schedules that include more 2-CdA and/or AraC. This is being tested in the Interfant-99 protocol especially designed for the treatment of infant ALL. The proB immunophenotype is probably the most important factor related to glucocorticoid resistance. However, since MLL gene rearrangements often occur concurrently with immunophenotype, their role in conferring steroid resistance cannot be excluded. MLL rearrangements also appear to be associated with 2-CdA sensitivity. Of great importance is that t(4;11) cases appear to be more resistant compared to other 11q23-translocated ALL cases. Age seems to be less important, at least for glucocorticoid resistance. However, in multivariate analysis, age superceded the role of immunophenotype (proB) and genotype (MLL rearranged) in the generation of L-ASP resistance and AraC sensitivity.
